{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:04:15Z","timestamp":1760234655371,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biomedical Science Institute of the CEU-Cardenal Herrera University","award":["BC\/ ICB-Santander 05\/12 and BC\/ ICB-Santander 06\/12"],"award-info":[{"award-number":["BC\/ ICB-Santander 05\/12 and BC\/ ICB-Santander 06\/12"]}]},{"name":"ESI InternationalChair@CEU-UCH","award":["ESI InternationalChair@CEU-UCH"],"award-info":[{"award-number":["ESI InternationalChair@CEU-UCH"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The variability of methicillin-resistant Staphylococcus aureus (MRSA), its rapid adaptive response against environmental changes, and its continued acquisition of antibiotic resistance determinants have made it commonplace in hospitals, where it causes the problem of multidrug resistance. In this study, we used molecular topology to develop several discriminant equations capable of classifying compounds according to their anti-MRSA activity. Topological indices were used as structural descriptors and their relationship with anti-MRSA activity was determined by applying linear discriminant analysis (LDA) on a group of quinolones and quinolone-like compounds. Four extra equations were constructed, named DFMRSA1, DFMRSA2, DFMRSA3 and DFMRSA4 (DFMRSA was built in a previous study), all with good statistical parameters, such as Fisher\u2013Snedecor F (&gt;68 in all cases), Wilk\u2019s lambda (&lt;0.13 in all cases), and percentage of correct classification (&gt;94% in all cases), which allows a reliable extrapolation prediction of antibacterial activity in any organic compound. The results obtained clearly reveal the high efficiency of combining molecular topology with LDA for the prediction of anti-MRSA activity.<\/jats:p>","DOI":"10.3390\/ijms22115823","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:22:15Z","timestamp":1622420535000},"page":"5823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular Topology for the Search of New Anti-MRSA Compounds"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2231-090X","authenticated-orcid":false,"given":"Jose I.","family":"Bueso-Bordils","sequence":"first","affiliation":[{"name":"Departamento de Farmacia, Universidad Cardenal Herrera-CEU, CEU Universities C\/Ram\u00f3n y Cajal s\/n, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-0250","authenticated-orcid":false,"given":"Pedro A.","family":"Alem\u00e1n-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Universidad Cardenal Herrera-CEU, CEU Universities C\/Ram\u00f3n y Cajal s\/n, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Mart\u00edn-Algarra","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Universidad Cardenal Herrera-CEU, CEU Universities C\/Ram\u00f3n y Cajal s\/n, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Duart","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Universidad Cardenal Herrera-CEU, CEU Universities C\/Ram\u00f3n y Cajal s\/n, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-0935","authenticated-orcid":false,"given":"Antonio","family":"Falc\u00f3","sequence":"additional","affiliation":[{"name":"ESI International Chair@CEU-UCH, Departamento de Matem\u00e1ticas, F\u00edsica y Ciencias Tecnol\u00f3gicas, Universidad Cardenal Herrera-CEU, CEU Universities San Bartolom\u00e9 55, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-5396","authenticated-orcid":false,"given":"Gerardo M.","family":"Ant\u00f3n-Fos","sequence":"additional","affiliation":[{"name":"Departamento de Farmacia, Universidad Cardenal Herrera-CEU, CEU Universities C\/Ram\u00f3n y Cajal s\/n, 46115 Alfara del Patriarca, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.meegid.2013.04.030","article-title":"Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus","volume":"21","author":"Uhlemann","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.1.5219.124-a","article-title":"\u201cCelbenin\u201d-resistant staphylococci","volume":"1","author":"Jevons","year":"1961","journal-title":"Br. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2011.01.007","article-title":"The global need for effective antibiotics-A summary of plenary presentations","volume":"14","author":"Alvan","year":"2011","journal-title":"Drug Resist. Updates"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Adegoke, A.A., Faleye, A.C., Singh, G., and Stenstr\u00f6m, T.A. (2016). Antibiotic-Resistant Superbugs: Assessment of the Interrelationshio of Occurrence in Clinical Settings and Environmental Niches. Molecules, 22.","DOI":"10.3390\/molecules22010029"},{"key":"ref_5","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: A review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cmrp.2018.01.001","article-title":"Methichillin-resistant Staphylococcus aureus: An update on the epidemiology, treatment options and infection control","volume":"8","author":"Boswihi","year":"2018","journal-title":"Curr. Med. Res. Pract."},{"key":"ref_7","unstructured":"World Health Organization (2021, March 16). WHO Priority Pathogens List for R&D of New Antibiotics. Available online: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1."},{"key":"ref_8","unstructured":"European Center for Disease Prevention and Control (2021, March 16). Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report for 2019, Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2019.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/nrmicro1289","article-title":"Immune evasion by staphylococci","volume":"3","author":"Foster","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF02026134","article-title":"Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus","volume":"13","author":"Pujol","year":"1994","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0140-6736(09)61999-1","article-title":"Community-associated methicillin-resistant Staphylococcus aureus","volume":"375","author":"DeLeo","year":"2010","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkr437","article-title":"MRSA: The first half century","volume":"67","author":"Moellering","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","unstructured":"World Health Organization (2021, March 16). 10 Facts on Antimicrobial Resistance. Available online: http:\/\/www.who.int\/features\/factfiles\/antimicrobial_resistance\/en\/."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.drudis.2016.06.013","article-title":"Descriptors and their selection methods in QSAR analysis: Paradigm for drug design","volume":"21","author":"Khan","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_16","first-page":"300","article-title":"El an\u00e1lisis multivariante en la investigaci\u00f3n con antimicrobianos","volume":"20","author":"Maldonado","year":"2007","journal-title":"Rev. Esp. Quimioterap."},{"key":"ref_17","first-page":"137","article-title":"Neural networks in building QSAR models","volume":"458","author":"Baskin","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00401706.1974.10489231","article-title":"Regressions by leaps and bounds","volume":"16","author":"Furnival","year":"1974","journal-title":"Technometrics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02289447","article-title":"A rationale and test for the number of factors in factor analysis","volume":"30","author":"Horn","year":"1965","journal-title":"Psychometrika"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cem.1180050305","article-title":"Examining large databases: A chemometric approach using principal component analysis","volume":"5","author":"Meglen","year":"1991","journal-title":"J. Chemom."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1472","DOI":"10.1002\/wcms.1472","article-title":"Quantitative structure\u2013activity relationship methods in the discovery and development of antibacterials","volume":"10","year":"2020","journal-title":"WIREs Comput. Mol. Sci."},{"key":"ref_22","first-page":"769","article-title":"The advancement of multidimensional QSAR for novel drug discovery\u2014where are we headed?","volume":"12","author":"Wang","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1573409911309020002","article-title":"Chemical graphs, molecular matrices and topological indices in chemoinformatics and quantitative structure-activity relationships","volume":"9","author":"Ovidiu","year":"2013","journal-title":"Curr. Comput. Drug. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/ci0342472","article-title":"The problem of overfitting","volume":"44","author":"Hawkins","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ccc.2010.11.005","article-title":"Optimal use of fluoroquinolones in the intensive care unit setting","volume":"27","author":"Rotschafer","year":"2011","journal-title":"Crit. Care Clin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cr030101q","article-title":"Bacterial topoisomerase inhibitors: Quinolone and pyridine antibacterial agents","volume":"105","author":"Mitscher","year":"2005","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Suay-Garcia, B., Falc\u00f3, A., Bueso-Bordils, J.I., Anton-Fos, G.M., P\u00e9rez-Gracia, M.T., and Alem\u00e1n-L\u00f3pez, P.A. (2020). Tree-based QSAR model for drug repurposing in the discovery of new antibacterial compounds against Escherichia coli. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120431"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/scientificamerican0986-40","article-title":"Predicting chemistry from topology","volume":"255","author":"Rouvray","year":"1986","journal-title":"Sci. Am."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11030-005-9012-2","article-title":"A novel simple QSAR model for the prediction of anti-HIV activity using multiple regression analysis","volume":"10","author":"Afantitis","year":"2006","journal-title":"Mol. Divers."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1021\/jm0580555","article-title":"Application of a mathematical topological pattern of antihistaminic activity for the selection of new drug candidates and pharmacology assays","volume":"49","author":"Duart","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zanni, R., Galvez-Llompart, M., Morell, C., Rodr\u00edguez-Henche, N., D\u00edaz-Laviada, I., Recio-Iglesias, M.C., Garcia-Domenech, R., and Galvez, J. (2015). Novel cancer chemotherapy hits by molecular topology: Dual Akt and Beta-catenin inhibitors. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124244"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wang, J., Land, D., Ono, K., Galvez, J., Zhao, W., Vempati, P., Steele, J.W., Cheng, A., Yamada, M., and Levine, S. (2014). Molecular topology as novel strategy for discovery of drugs with Ab lowering and anti-aggregation dual activities for Alzheimer\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092750"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bueso-Bordils, J.I., Alem\u00e1n-L\u00f3pez, P.A., Suay-Garc\u00eda, B., Mart\u00edn-Algarra, R., Duart, M.J., Falc\u00f3, A., and Ant\u00f3n-Fos, G.M. (2020). Molecular topology for the discovery of new broad-spectrum antibacterial drugs. Biomolecules, 10.","DOI":"10.3390\/biom10091343"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejmech.2017.07.010","article-title":"Topological pattern for the search of new active drugs against methicillin resistant Staphylococcus aureus","volume":"138","author":"Duart","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1021\/ci970002b","article-title":"The E-state as an extended free valence","volume":"37","author":"Kier","year":"1997","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/ci00024a017","article-title":"Topological approach to drug design","volume":"35","author":"Soler","year":"1995","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1021\/ja00856a001","article-title":"On characterization of molecular branching","volume":"97","author":"Randic","year":"1975","journal-title":"J. Am. Chem. Soc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/BF02840338","article-title":"Correlations between topological features and physicochemical properties of molecules","volume":"93","author":"Jain","year":"1984","journal-title":"Proc. Indian Acad. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \u201ccyclopropyl fragment\u201d is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/j.bmcl.2006.03.103","article-title":"Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety","volume":"16","author":"Foroumadi","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0263-7855(96)00081-1","article-title":"Pharmacological distribution diagrams: A tool for de novo drug design","volume":"14","author":"Popa","year":"1996","journal-title":"J. Mol. Graph."},{"key":"ref_42","unstructured":"CLSI (2012). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement: CLSI Document M100-S22, Clinical and Laboratory Standards Institute."},{"key":"ref_43","unstructured":"(2000). DESMOL13 Software, Unidad de Investigaci\u00f3n de Dise\u00f1o de F\u00e1rmacos y Conectividad Molecular, Facultad de Farmacia, Universitat de Val\u00e8ncia."},{"key":"ref_44","unstructured":"Hall, L.H. (1995). MOLCONN-Z Software, Eastern Nazarene College."},{"key":"ref_45","unstructured":"Dixon, W.J. (1990). BMDP Statistical Software, University of California."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:10:22Z","timestamp":1760163022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/11\/5823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijms22115823"],"URL":"https:\/\/doi.org\/10.3390\/ijms22115823","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,5,29]]}}}